The Epidemiology Research Core (ERC) supports population-based research by providing access to metropolitan Detroit cancer cases and the cancer registry data for research. The Core also provides epidemiology consulting and collaborates with KCI members conducfing investigations in cancer prevention, etiology, treatment and outcomes. This mission is achieved through services including rapid case ascertainment (RCA) for population-based case enrollment;collection of medical records and biospecimens for population-tjased cases;abstracting medical records for study-specific information for population-based cases;linkage of datasets to patient data for diagnostic, treatment, and outcomes data;identifying population-based control groups;oversight and support of population-based study participant recruitment and interviewing;and epidemiologic expertise and collaboration for the conduct of population-based investigations of cancer. These objectives are achievable because WSU and KCI house the Metropolitan Detroit Cancer Surveillance System (MDCSS), an NCI-funded population-based Surveillance Epidemiology and End Results (SEER) registry covering the metropolitan Detroit population of four million residents. This population represents a large number of minorities, with -25% of the 25,000 annual cancer diagnoses in the SEER catchment area being African American, making the population ideal for the study of health disparities. The ERC benefits KCI by centralizing access to SEER data and standardizing patient, physician and hospital interactions for research relying on identification of and access to study participants for populafion-based research.

Public Health Relevance

The ERC provides the necessary support to KCI members and other investigators for access to and utilization of cancer registry data and patients for entry into population-based investigations of cancer prevention, etiology, treatment and outcomes. This type of population-based cancer research is made possible by providing investigator access to the MDCSS and national SEER population data through the ERC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-32
Application #
8600860
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
32
Fiscal Year
2014
Total Cost
$154,458
Indirect Cost
$52,842
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Colacino, Justin A; Azizi, Ebrahim; Brooks, Michael D et al. (2018) Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling. Stem Cell Reports 10:1596-1609
Herroon, Mackenzie K; Rajagurubandara, Erandi; Diedrich, Jonathan D et al. (2018) Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin. Sci Rep 8:40
Guastella, Anthony R; Michelhaugh, Sharon K; Klinger, Neil V et al. (2018) Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors. J Neurooncol 139:239-249
Blocker, Stephanie J; Shields, Anthony F (2018) Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery. Mol Imaging Biol 20:340-351
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294

Showing the most recent 10 out of 826 publications